MedTrace Logo

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

NCT01420081 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.

Conditions

  • Endometrial Neoplasms

Interventions

DRUG

PF-05212384

154mg IV weekly

DRUG

PF-05212384

154mg IV weekly

DRUG

PF-05212384

154mg IV weekly

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-19
Primary Completion
2014-04-30
Completion
2015-12-25

Countries

  • United States
  • Australia
  • Canada
  • Japan
  • Poland
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420081 on ClinicalTrials.gov